Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PRIME Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

NCT01974895
View directory record Official record
Conditions
Influenza
Interventions
FluLaval® Quadrivalent, Fluzone®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
12
States / cities
Sacramento, California • West Covina, California • Altamonte Springs, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 25, 2026, 2:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Infant Immunity Comparison of Breastfed and Bottlefed Infants

NCT02568579
View directory record Official record
Conditions
Infant Immunity Response and Immunoglobulin Diversity
Interventions
blood sample/ stool sample
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

NCT00912496
View directory record Official record
Conditions
Influenza
Interventions
MF-59, A/Anhui/05, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
637 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 25, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional

Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia

NCT00005986
View directory record Official record
Conditions
Leukemia
Interventions
busulfan, cyclophosphamide, filgrastim, recombinant interferon alfa, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Not applicable Interventional Results available

The Effect of Priming of Questionnaire Content on Grip Strength in Patients With Hand and Upper Extremity Illness

NCT02493127
View directory record Official record
Conditions
Hand and Upper Extremity Illness
Interventions
Standard PCS, Grip Strength, Positively Adjusted PCS
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 25, 2026, 2:38 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neurocognitive Mechanisms of Sentence Production Impairment in Aphasia

NCT06405594
View directory record Official record
Conditions
Aphasia, Acquired, Stroke, Healthy Aging
Interventions
Language Condition
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

NCT02151448
View directory record Official record
Conditions
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Interventions
DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod
Biological · Drug
Lead sponsor
David Bartlett
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 25, 2026, 2:38 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The PRIME Study: A Randomized, Controlled, Prospective Study

NCT04549935
View directory record Official record
Conditions
Patient Preference, Patient Outcomes, Post-Operative Inflammation, Grade of Post-Operative Cystoid Macular Edema, Rate of Post-Operative Cystoid Macular Edema
Interventions
Dextenza, Topical Prednisolone
Drug
Lead sponsor
Vance Thompson Vision - MT
Other
Eligibility
22 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 25, 2026, 2:38 AM EDT
Recruiting Phase 2 Interventional

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

NCT07078604
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Chemotherapy, Computed Tomography, Sargramostim, Biospecimen Collection, Positron Emission Tomography (PET), Image Guided Biopsy
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

NCT00801697
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Vaccine, DNA Vaccine placebo, rAd35, rAd35 placebo, rAd5, rAd5 placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety of Three Experimental HIV Vaccines

NCT00000946
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
HIV p24/MF59 Vaccine, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2001
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 25, 2026, 2:38 AM EDT
Completed No phase listed Observational

Lactate for Energy and Neurocognition

NCT05207397
View directory record Official record
Conditions
Healthy Aging, Alzheimer Disease
Interventions
Lactate infusion
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
60 Years to 95 Years
Enrollment
24 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00085423
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, sargramostim, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Oct 25, 2026, 2:38 AM EDT
Not yet recruiting Not applicable Interventional

Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD)

NCT05509842
View directory record Official record
Conditions
Parkinson Disease
Interventions
rTMS
Device
Lead sponsor
University of Michigan
Other
Eligibility
45 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 2:38 AM EDT
Enrolling by invitation Not applicable Interventional

Engaging Patients in Adherence Interventions Using Behavioral Science

NCT06543394
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Primer postcard, Control recruitment letter, Behavioral theory-informed recruitment letter, 2 phone calls, 4 phone calls
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Phase 2 Interventional

Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients

NCT00219362
View directory record Official record
Conditions
HIV Infection
Interventions
one injection of vCP1452 at W0, W4, W8 and W20, one injection of vCP1452 at W4, W8 and W20, one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20
Biological
Lead sponsor
Objectif Recherche Vaccins SIDA
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Oct 25, 2026, 2:38 AM EDT
Withdrawn Phase 2 Interventional

Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer

NCT06557278
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
AlloStim, Bavencio
Biological · Drug
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Miami Beach, Florida • Brooklyn, New York • Shirley, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 25, 2026, 2:38 AM EDT
Withdrawn Phase 2 Interventional

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

NCT05445882
View directory record Official record
Conditions
Castration Resistant Prostate Cancer
Interventions
Bintrafusp alfa, N-803, BN-Brachyury
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 25, 2026, 2:38 AM EDT
Recruiting Not applicable Interventional

Precise Robotically IMplanted Brain-Computer InterfacE

NCT06429735
View directory record Official record
Conditions
Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Quadriplegia/Tetraplegia, Tetraplegic; Paralysis
Interventions
N1 Implant, R1 Robot
Device
Lead sponsor
Neuralink Corp
Industry
Eligibility
22 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Phoenix, Arizona • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Not applicable Interventional Results available

Repetitive Transcranial Magnetic Stimulation Use in Acute Stroke

NCT01922986
View directory record Official record
Conditions
Stroke
Interventions
active rTMS, sham rTMS, conventional stroke therapy
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 25, 2026, 2:38 AM EDT
Recruiting Phase 1 Interventional

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

NCT05433142
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
XmAb819
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
20
States / cities
Phoenix, Arizona • Duarte, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

NCT01196988
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 17 Years
Enrollment
3,027 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
14
States / cities
Sacramento, California • Boca Raton, Florida • Wichita, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

NCT02963909
View directory record Official record
Conditions
Zika Virus Infection
Interventions
IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 25, 2026, 2:38 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

NCT07382739
View directory record Official record
Conditions
Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab, Relapsed Refractory Multiple Myeloma (RRMM), Extramedullary Disease in Multiple Myeloma, Paramedullary Disease, PMD
Interventions
Elranatamab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 25, 2026, 2:38 AM EDT